The company is committed to the development of a variety of innovative cell therapy products for rare diseases, cancer, etc.
Q1 2022 c-suite not found.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 15, 2021 | Series Unknown | ¥100M | 4 | Sequoia Capital China | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Sequoia Capital China | Yes | Series Unknown |
Stow Capital | — | Series Unknown |
CD Capital | — | Series Unknown |
Fang Group | — | Series Unknown |